ORALAIR

This brand name is authorized in Austria, Canada, Croatia, Estonia, France, Ireland, Lithuania, Netherlands, New Zealand, Poland, Romania, Spain, Tunisia.

Active ingredients

The drug ORALAIR contains one active pharmaceutical ingredient (API):

1	Grass pollen
	Read more about Grass pollen

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ORALAIR Tablets	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
V01AA02	Grass pollen	V Various → V01 Allergens → V01A Allergens → V01AA Allergen extracts
Discover more medicines within V01AA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02381885, 02381893
EE	Ravimiamet	1415887, 1415911, 1415922
ES	Centro de información online de medicamentos de la AEMPS	71953, 71954
FR	Base de données publique des médicaments	60425707, 62764332
HR	Agencija za lijekove i medicinske proizvode	HR-H-086623922, HR-H-592791526
LT	Valstybinė vaistų kontrolės tarnyba	1037548, 1037549, 1055021
NL	Z-Index G-Standaard, PRK	205648, 205656
NZ	Medicines and Medical Devices Safety Authority	14761, 14762
PL	Rejestru Produktów Leczniczych	100226818, 100226853
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W55365001, W55366001, W55366002
TN	Direction de la Pharmacie et du Médicament	3653041, 3653042